Diagnosis bleak if Affordable Care Act repealed
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Tri-county hospitals expanding facilities
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen updates agreement with DaVita for dialysis treatment
Thousand Oaks biotech company Amgen entered into a six-year supply agreement with DaVita for dialysis treatments, the company announced on Jan. 9. Under the terms of the new agreement, Amgen will supply DaVita with Epogen and Aranesp for agents to stimulate red blood cells in dialysis treatment in the United States and Puerto Rico. The Read More →
Amgen partners with Immatics Biotechnologies to develop cancer drugs
Thousand Oaks biotech company Amgen formed a potential $500 million partnership with Immatics Biotechnologies GmbH to research and develop next-generation, T-cell engaging bispecific immunotherapies targeting multiple cancers, the company announced on Jan. 9. Under the terms of the agreement, Immatics will receive $30 million upfront and can receive more than $500 million in development, regulatory Read More →
Elings donates $4 million to Cancer Center of Santa Barbara
Philanthropist Virgil Elings donated $4 million to the new Cancer Center of Santa Barbara to open in the fall at 540 W. Pueblo St. The $53 million cancer center, which merged with Sansum Clinic in 2012, will be renamed the Ridley-Tree Cancer Center to honor Lady Leslie Ridley-Tree’s $10.73 million donation. The Elings Oncology Building Read More →
Uncertainty looms for tri-county nonprofits under Trump
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen shares climb after judge upholds Repatha patents
A ruling in a patent law case regarding a new anti-cholesterol drug involving Thousand Oaks biotech giant Amgen has skyrocketed Amgen shares. Amgen filed a patent infringement lawsuit against Sanofi and Regeneron in the U.S. District Court of Delaware in October 2014 to block the development and sale of the drug Praluent, which was developed Read More →
